SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-009253 to BullFrog AI Holdings, Inc. (BFRG)

BullFrog AI Holdings, Inc.
Date: Aug. 13, 2024 · CIK: 0001829247 · Accession: 0000000000-24-009253

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-281341

Date
August 13, 2024
Author
Dane Saglio
Form
UPLOAD
Company
BullFrog AI Holdings, Inc.

Letter

August 13, 2024 Dane Saglio Chief Financial Officer Bullfrog AI Holdings, Inc. 325 Ellington Blvd., Unit 317 Gaithersburg, MD 20878 Re:Bullfrog AI Holdings, Inc. Registration Statement on Form S-3 Filed August 7, 2024 File No. 333-281341 Dear Dane Saglio: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Arthur Marcus, Esq.

Show Raw Text
August 13, 2024
Dane Saglio
Chief Financial Officer
Bullfrog AI Holdings, Inc.
325 Ellington Blvd., Unit 317
Gaithersburg, MD 20878
Re:Bullfrog AI Holdings, Inc.
Registration Statement on Form S-3
Filed August 7, 2024
File No. 333-281341
Dear Dane Saglio:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Arthur Marcus, Esq.